Apta Biosciences

Please note: Apta Biosciences is no longer trading

In April 2014, synthetic molecule business Apta Biosciences successfully raised £1,850,000 to continue undergoing validation work with partners for therapeutics. The business completed its second round of funding in August 2015, raising £964,550 to support product development for its new generation of special molecules.

The story

Apta produces Adaptamers; molecules that have much in common with antibodies, but offer a better performance because of their ease to make and use. Most of us probably don’t think about antibodies too often, but we have a lot to thank them for: our own natural antibodies help us to fight viruses and dangerous bacteria every single day. This is clearly reflected by the market for antibodies and their alternatives, which is deemed to be worth an impressive $60bn p.a.

Apta has created a new generation of synthetic molecules called Seligos. Seligos are a kind of affinity reagent, which bind to specifically targeted cells in order to identify, track, capture and influence their activity to identify and treat diseases.

Where are they now?

Apta Biosciences entered administration in July 2020.

See current opportunities